A Phase I Study of MK8669 in Patients With Metastatic or Locally Advanced Solid Tumors
Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Any clinical or laboratory adverse experience.
Duration of Treatment
Japan: Pharmaceuticals and Medical Devices Agency